These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 33325754)

  • 1. Enfortumab vedotin - next game-changer in urothelial cancer.
    Maas M; Stühler V; Walz S; Stenzl A; Bedke J
    Expert Opin Biol Ther; 2021 Jul; 21(7):801-809. PubMed ID: 33325754
    [No Abstract]   [Full Text] [Related]  

  • 2. Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.
    McGregor BA; Sonpavde G
    Expert Opin Investig Drugs; 2019 Oct; 28(10):821-826. PubMed ID: 31526130
    [No Abstract]   [Full Text] [Related]  

  • 3. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
    Mantia CM; Sonpavde G
    Expert Rev Anticancer Ther; 2022 May; 22(5):449-455. PubMed ID: 35466857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Paradigm shift in systemic therapy for metastatic urothelial carcinoma-antibody-drug conjugates (ADCs) and fibroblast growth factor receptor (FGFR) inhibitors].
    Casuscelli J; von Amsberg G; Retz M
    Urologie; 2024 Oct; 63(10):1002-1010. PubMed ID: 39235511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
    Yu EY; Petrylak DP; O'Donnell PH; Lee JL; van der Heijden MS; Loriot Y; Stein MN; Necchi A; Kojima T; Harrison MR; Hoon Park S; Quinn DI; Heath EI; Rosenberg JE; Steinberg J; Liang SY; Trowbridge J; Campbell M; McGregor B; Balar AV
    Lancet Oncol; 2021 Jun; 22(6):872-882. PubMed ID: 33991512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The biology and rationale of targeting nectin-4 in urothelial carcinoma.
    Heath EI; Rosenberg JE
    Nat Rev Urol; 2021 Feb; 18(2):93-103. PubMed ID: 33239713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enfortumab Vedotin in urothelial cancer.
    Alt M; Stecca C; Tobin S; Jiang DM; Sridhar SS
    Ther Adv Urol; 2020; 12():1756287220980192. PubMed ID: 33447264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enfortumab vedotin to treat urothelial carcinoma.
    Hanna KS
    Drugs Today (Barc); 2020 May; 56(5):329-335. PubMed ID: 32406880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
    Koshkin VS; Henderson N; James M; Natesan D; Freeman D; Nizam A; Su CT; Khaki AR; Osterman CK; Glover MJ; Chiang R; Makrakis D; Talukder R; Lemke E; Olsen TA; Jain J; Jang A; Ali A; Jindal T; Chou J; Friedlander TW; Hoimes C; Basu A; Zakharia Y; Barata PC; Bilen MA; Emamekhoo H; Davis NB; Shah SA; Milowsky MI; Gupta S; Campbell MT; Grivas P; Sonpavde GP; Kilari D; Alva AS
    Cancer; 2022 Mar; 128(6):1194-1205. PubMed ID: 34882781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma.
    Halford Z; Anderson MK; Clark MD
    Ann Pharmacother; 2021 Jun; 55(6):772-782. PubMed ID: 32945172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enfortumab vedotin in the treatment of urothelial cancers and beyond.
    Wong RL; Yu EY
    Future Oncol; 2022 Sep; 18(27):3067-3084. PubMed ID: 36004667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetic Modeling and Exposure-Response Analysis for the Antibody-Drug Conjugate Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Carcinoma.
    Zuo P; Bonate P; Garg A; Matsangou M; Tang M
    Clin Pharmacol Ther; 2024 Nov; 116(5):1278-1288. PubMed ID: 39039635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
    Hanna KS
    Drugs; 2020 Jan; 80(1):1-7. PubMed ID: 31823332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enfortumab Vedotin: Nursing Perspectives on the Management of Adverse Events in Patients With Locally Advanced or Metastatic Urothelial Carcinoma.
    Pace A; Brower B; Conway D; Leis D
    Clin J Oncol Nurs; 2021 Apr; 25(2):E1-E9. PubMed ID: 33739346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.
    Rosenberg J; Sridhar SS; Zhang J; Smith D; Ruether D; Flaig TW; Baranda J; Lang J; Plimack ER; Sangha R; Heath EI; Merchan J; Quinn DI; Srinivas S; Milowsky M; Wu C; Gartner EM; Zuo P; Melhem-Bertrandt A; Petrylak DP
    J Clin Oncol; 2020 Apr; 38(10):1041-1049. PubMed ID: 32031899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.
    Uchimoto T; Matsuda T; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Saruta M; Hashimoto M; Higashio T; Tsuchida S; Nishimura K; Tsujino T; Nakamura K; Fukushima T; Nishio K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Fujita K; Kimura T; Ohno Y; Shiroki R; Uemura H; Azuma H
    Target Oncol; 2024 Jul; 19(4):635-644. PubMed ID: 38807017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors.
    Tang M; Garg A; Bonate PL; Rosenberg JE; Matsangou M; Kadokura T; Yamada A; Choules M; Pavese J; Nagata M; Tenmizu D; Koibuchi A; Heo N; Wang L; Wojtkowski T; Hanley WD; Poondru S
    Clin Pharmacokinet; 2024 Apr; 63(4):423-438. PubMed ID: 38609704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma.
    Takahashi S; Uemura M; Kimura T; Kawasaki Y; Takamoto A; Yamaguchi A; Melhem-Bertrandt A; Gartner EM; Inoue T; Akazawa R; Kadokura T; Tanikawa T
    Invest New Drugs; 2020 Aug; 38(4):1056-1066. PubMed ID: 31444589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.
    Uchimoto T; Tsuchida S; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Saruta M; Hashimoto M; Higashio T; Matsuda T; Nishimura K; Tsujino T; Nakamura K; Fukushima T; Nishio K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Fujita K; Kimura T; Ohno Y; Shiroki R; Uemura H; Azuma H
    Target Oncol; 2024 May; 19(3):401-410. PubMed ID: 38546942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options.
    Park I; Lee JL
    Korean J Intern Med; 2020 Jul; 35(4):834-853. PubMed ID: 32668516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.